Showing results (111-120 of 143) with videos related to
Sort By:
Pageof 15
European Heart Journal Open|December 11, 2024
Vascular and inflammatory biomarkers of cardiovascular events in non-steroidal anti-inflammatory drug usersRicky Vaja, Plinio Ferreira, Laura Portas, et al.Therapeutic Advances in Neurological Disorders|January 28, 2025
A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status updateKerstin Hellwig, Melinda Magyari, Thomas M MacDonald, et al.The Lancet. Diabetes & Endocrinology|October 23, 2015
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trialMorris J Brown, Bryan Williams, Steve V Morant, et al.The Lancet. Diabetes & Endocrinology|April 16, 2018
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudiesBryan Williams, Thomas M MacDonald, Steve V Morant, et al.BMJ Open|July 12, 2014
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemiaThomas M MacDonald, Ian Ford, George Nuki, et al.Journal of the American Heart Association|November 20, 2017
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled TrialThomas M MacDonald, Bryan Williams, David J Webb, et al.Hypertension (Dallas, Tex. : 1979)|July 30, 2024
UMOD Genotype-Blinded Trial of Ambulatory Blood Pressure Response to TorasemideLinsay McCallum, Stefanie Lip, Alex McConnachie, et al.Lancet (London, England)|November 12, 2020
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trialIsla S Mackenzie, Ian Ford, George Nuki, et al.Health Technology Assessment (Winchester, England)|March 12, 2021
The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTsEmily Herrett, Elizabeth Williamson, Kieran Brack, et al.Drug Safety|May 29, 2019
Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350Joan Fortuny, Alicia Gilsenan, Miguel Cainzos-Achirica, et al.Pageof 15